

Grade 1
Grade 2
Grade 3
Grade 4
Grade 5
Percentage of Subjects
0
10
20
30
40
50
60
70
80
90
100
Any TEAE*+
Any Related TEAE+
Neutropenia
Cytokine Release Syndrome
Fatigue
Thrombocytopenia
Decreased Appetite
Nausea
Anaemia
Constipation
Diarrhea
Neutropenia
Anemia
Thrombocytopenia
TEAEs Occurring in ≥20% of Patients
Laboratory Abnormalities

FIG. 1




NT
CRS
CRS or NT
60% with no
CRS or NT
% without CRS or Neurotoxicity
100
80
60
40
20
0
0
7
14
21
28
Days after CAR+ T cells
At risk
CRS 55 43 37 37 35
NT 55 53 47 44 42
CRS or NT 55 43 37 37 35

FIG. 2

FIG. 3A


FULL
Population
ORR(95% CI)
N
Overall 51.2(35.1,67.1) 41
Dbl/Trpl Hit 81.8(48.2,97.7) 11
Dbl/Trpl Hit/ Dbl expressors 64.7(38.3,85.8) 17
Primary Refractory 31.3(11,58.7) 16
Never in CR 48.3(29.4,67.5) 29
Chemosensitive 66.7(29.9,92.5) 9
Chemorefractory 46.9(29.1,65.3) 32
Relapse<12m from last ASCT 90.9(58.7,99.8) 11
SD/D to last chemo 23.8(8.2,47.2) 21
Post-Allo 0(0,60.2) 4
ECOG 0-1 58.3(40.8,74.5) 36
ECOG 2 0(0,52.2) 5
tFL 42.9(9.9,81.6) 7
tMZL/CLL 0(0,52.2) 5
DLBCL NOS 60.7(40.6,78.5) 28
0 10 20 30 40 50 60 70 80 90 100
M3 ORR (95% CI)



CORE
Population ORR(95% CI) N
Core Pop 65.6(46.8,81.4) 32
DL1S 57.9(33.5,79.7) 19
DL1D 75(19.4,99.4) 4
DL2S 77.8(40,97.2) 9
Dbl/Trpl Hit 100(66.4,100) 9
Dbl/Trpl/Hit/Dbl expressors 84.6(54.6,98.1) 13
Primary Refractory 50(18.7,81.3) 10
Never in CR 66.7(43,85.4) 21
Chemosensitive 85.7(42.1,99.6) 7
Chemorefractory 60(38.7,78.9) 25
Relapse<12m from last ASCT 100(69.2,100) 10
SD/PD to last chemo 33.3(11.8,61.6) 15
Post-Allo 0(0,70.8) 3
ECOG 0 75(50.9,91.3) 20
ECOG 1 50(21.1,78.9) 12
tFL 50(11.8,88.2) 6
DLBCL NOS 68(46.5,85.1) 25
0 10 20 30 40 50 60 70 80 90 100
M3 ORR (95% CI)

FIG. 3B

FIG. 4A

FULL



% in response
100
80
60
40
20
0
0
3
6
9
12
Duration of Response (Months)
CR
CR/PR
PR
At risk
CR/PR 41 10 6 5 0
CR 28 10 6 5 0
PR 13 0
% survival
100
80
60
40
20
0
0
3
6
9
12
Overall Survival (Months)
CR/PR
All subjects
Non Responder
At risk
All 54 30 14 8 1
CR/PR 41 26 12 8 1
Non Responder 13 4 2 0

FIG. 4B

CORE



% survival
100
80
60
40
20
0
CR/PR
All subjects
Non Responder
0
3
6
9
12
Overall Survival (Months)
At risk
All 44 26 13 8 1
CR/PR 38 23 11 8 1
Non Responder 6 3 2 0
% in response
100
80
60
40
20
0
CR
CR/PR
PR
0
3
6
9
12
Duration of Response (Months)
At risk
CR/PR 38 10 6 5 0
CR 26 10 6 5 0
PR 12 0

FIG. 5A



Dose Level
CD4+ CAR
CD8+ CAR
100
10
1
0.1
0.01
0.001
DL2S
DL1S
Med AUC0-28 (Q1, Q3)
DL1: 182 (82, 636)
DL2: 350 (103, 1468)
Med AUC0-28 (Q1, Q3)
DL1: 114 (40, 1132)
DL2: 1628 (235, 3957)
1
2
4
8
11
15
22
29
Time (Days)
Dose Level
DL1S (n=29)
DL2S (n=18)

FIG. 5B

Month 3 Response





FIG. 5C


Neurotoxicity
CD4+ CAR
CD8+ CAR
Any
None
Med AUC0-28 (Q1, Q3)
No NT: 109 (31, 346)
Any NT: 3729 (465, 15717)
Med AUC0-28 (Q1, Q3)
No NT: 235 (55, 1087)
Any NT: 8315 (882, 59028)
Time (Days)
Neurotoxicity
None (n=32)
Any (n=9)



Spontaneous
re-expansion
CD4
CD3
CD8
First
expansion
Disease
progression
Biopsy
CAR T cell
Dosing
Days
CAR+ Cells/μL Blood
25
20
15
5
0
0
30
60
90
120
150
180
210

FIG. 6A

FIG. 6C





FIG. 6B






FIG. 6E



FIG. 6D

FIG. 6G





FIG. 6F





Neurotoxicity
None
Any
Unit
10,000
1000
100
10
1
0.1
LDH
Ferritin
CRP
IL-6
IL-8
IL-10
IL-15
TNF-α
IFN-γ
IFN-α2
MCP-1
MIP-1β
Eotaxin
G-CSF
IL-1Rα
IL-1β
IP-10
Perforin
Parameter
Units: LDH (U/L), Ferritin (ng/ml), CRP (mg/L), cytokines (pg/mL)

FIG. 7



Patients Treated ≥6 Months Ago
Patients Treated ≥3 Months Ago
Patients Treated ≥1 Month Ago
9/10 Patients in Response at 3 Months Remain in response at 6 Months
Best Overall Response
CR
PR
SD
PD
NE
Ongoing Response
Time to First CR or PR
(SD,PR converted to PR or CR)
CR
PR
SD
Dose Level
DL1S
DL2S
DL1D
b, c
b
Full
Core
0
1
3
6
9
12
Progression-Free Time (Months)

FIG. 8

FIG. 9B



CAR+ in Bone Marrow, Cells/µL
CD4
CD8
CAR+ Cells/µL in Blood
1000
100
10
1
0.1
0.01
0.001

FIG. 9A



CAR+ T cells/µL; copies/µg
CD3
qPCR
qPCR
CD3
Study Day
1
2
4
8
11
15
22
29
100,000
10,000
1000
100
10
1
0.1
0.01
0.001

FIG. 10A





FIG. 10B





AUC0-28 (cells*day/μL)
1000000
100000
10000
1000
100
10
1
0.1
CD3+
DL1
DL2
CD4+
DL1
DL2
CD8+
DL1
DL2

FIG. 11A



Cmax (cells/μL)
10000
1000
100
10
1
0.1
0.01
DL1
DL2
CD3+
DL1
DL2
CD4+
DL1
DL2
CD8+

FIG. 11B

FIG. 12B




FIG. 12A




FIG. 12D





FIG. 12C






FIG. 13A




FIG. 13B



CD3+ Cmax < 500 (n = 55)
CD3+ Cmax > 500 (n = 7)
10000
1000
100
10
1
0.1
pg/mL
IL-7
IL-15
MIP-1α
TNF-α

FIG. 14A




CD3+ Cmax < 500 (n = 68)
CD3+ Cmax > 500 (n = 9)
pg/mL
10000
1000
100
10
1
0.1
IL-6
IL-10
IL-16
IFN-γ
TNF-α
MIP-1α
MIP-1β
MCP-1
CXCL10

FIG. 14B

FIG. 15


CD3 AUC0-28 (cells*day/µL)
10000
100
1
SPD (per cm2) Pre-Lymphodepletion
100
50
10
5
Dose Level 1
Dose Level 2



CRS Grade 1-4
CRS Grade 0
Units
10000
1000
100
10
1
0.1
Ferritin
CRP
IL-10
IL-15
IL-16
TNF-α
MIP-1β

FIG. 16A



NT Grade 1-4
NT Grade 0
Units
10000
1000
100
10
1
0.1
Ferritin
CRP
D-dimer
IL-6
IL-15
TNF-α
MIP-1α

FIG. 16B



CRS
No Toxicity
Toxicity
Units
10000
1000
100
10
No CRS
Any CRS
No CRS
Any CRS
SPD, cm2*
p=0.0003
LDH, U/L*
p<0.0001
NT
No NT
Any NT
No NT
Any NT
SPD, cm2*
p=0.0059
LDH, U/L*
p=0.178

FIG. 17



Pre-LDC SPD (cm²)
300
200
100
50
25
0
10/13 (77%)
7/36 (19%)
Pre-LDC LDH (U/L)
10²
10³
10⁴
Grade 0 CRS
Grade 1-4 CRS
7/13 (54%)
4/37 (11%)
Grade 0 NT
Grade 1-4 NT

FIG. 18A



NT
CRS
NT
CRS
NT
CRS
NT
CRS
LDH ≥500
SPD ≥ 50
LDH ≥500 or SPD ≥ 50
0.125
0.25
0.5
1
2
4
8
16
32
Odds Ratio Estimate (95% CI)

FIG. 18B



NT
CRS
LDH ≥500
SPD ≥ 50
LDH ≥500 and SPD ≥ 50
LDH <500 and SPD < 50
0.03
0.125
0.25
0.5
1
2
4
8
16
32
Odds Ratio Estimate (95% CI)

FIG. 18C



No Response at 3 Months
Response at 3 Months
Units
10000
1000
100
10
1
0.1
SPD
LDH
Ferritin
CRP
D-dimer
SAA-1
IL-6
IL-10
IL-15
IL-16
TNF-α
IFN-γ
MIP-1α
CXCL10

FIG. 19



no CRS (grade 0)
any CRS (grade 1-4)
Units
10000
1000
100
10
1
0.1
CRP
SAA-1
IL-2
IL-6
IL-15
TNF-α
MCP-1
MIP-1β
CXCL10
CCL13

FIG. 20A



no NT (grade 0)
any NT (grade 1-4)
Units
10000
1000
100
10
1
0.1
CRP
IL-2
IL-6
IL-10
IL-15
TNF-α
MIP-1α
MIP-1β
MCP-1
CXCL10
CCL13

FIG. 20B



SD/PD
CR/PR
CXCL10
MIP-1a
TNF-a
LTa
IL-8
IL-6
SAA-1
CRP
Units
10000
1000
100
10
1
0.1

FIG. 21A




Month 3 SD/PD
Month 3 CR/PR
Units
10000
1000
100
10
1
0.1
CRP
SAA
IL-1
IL-5
IL-6
IL-7
IL-8
IL-13
TNFa
IFN-γ
CXCL10
MCP-1
MIP-1a
MIP-1b
TGF-β1

FIG. 21B

FIG. 22


Population
ORR (95% CI)
n
CORE Patient Population
65.4 (50.9, 78)
52
tFL
76.9 (46.2, 95)
13
DLBCL NOS
61.5 (44.6, 76.6)
39
Double/triple hit or double expressor
83.3 (58.6, 96.4)
18
Double/triple hit
84.6 (54.6, 98.1)
13
Double expressor
80 (28.4, 99.5)
13
Never in CR
73.1 (52.2, 88.4)
26
Chemosensitive
66.7 (38.4, 88.2)
15
Chemorefractory
64.9 (47.5, 79.8)
37
Relapse <12m from ASCT
84.6 (54.6, 98.1)
13
SD/PD to last chemo
54.2 (32.8, 74.4)
24
Stage 3/4
62.2 (44.8, 77.5)
37
Stage 1/2
76.9 (46.2, 95)
13
IPI 3-5
42.1 (20.3, 66.5)
19
IPI 0-2
78.8 (61.1, 91)
33
0
10
20
30
40
50
60
70
80
90
100
Month 3 ORR (95% CI)



FULL
mDOR (95% CI)
CR: 9.2 mos (3.7, NR)
All: 5.0 mos (2.8, NR)
PR: 2.1 mos (1.0, 5.0)
% in response
100
80
60
40
20
0
0
3
6
9
12
15
Time from first response (months)
At Risk
CR 46 24 13 8 2 2
PR 19 2 0
All 65 26 13 8 2 2

FIG. 23A



CORE
mDOR (95% CI)
CR: NR (5.0, NR)
All: 9.2 mos (3.7, NR)
PR: 2.1 mos (1.0, 5.0)
% in response
100
80
60
40
20
0
Time from first response (months)
0
3
6
9
12
15
At Risk
CR 36 22 12 7 1 1
PR 16 2 0
All 52 24 12 7 1 1

FIG. 23B



FULL
CR : NR (13.7, NR); 92% (78, 98)
All : NR (9.0, NR); 78% (66, 86)
PR : 9.0 mos (3.8, NR); 75% (40, 91)
Nonresponders: 5.4 mos (1.5, NR); 46% (21, 68)
mOS (95% CI); 6 mo OS (95% CI)
Median F/U=6.2 months
% Survival
100
80
60
40
20
0
0 3 6 9 12 15 18
Overall Survival (months)
At Risk
All 88 53 37 20 13 4 0
CR 46 35 25 16 12 4 0
PR 19 12 8 2 0
Non-responder 23 6 4 2 1 0

FIG. 23C



CORE
CR : NR (NR, NR); 94% (78, 98)
All : NR (NR, NR); 86% (73, 93)
PR : 9.0 mos (4.9, NR); 81% (44, 95)
Nonresponders: 6.2 mos (0.6, NR); 66% (33, 86)
mOS (95% CI); 6 mo OS (95% CI)
Median F/U=6.2 months
% Survival
100
80
60
40
20
0
0
3
6
9
12
15
18
Overall Survival (months)
At Risk
All 65 39 30 15 9 3 0
CR 36 26 20 12 9 3 0
PR 16 11 8 2 0
Non-responder 13 2 2 1 0

FIG. 23D




Grade 1
Grade 2
Grade 3
Grade 4
Grade 5
Percentage of Patients
0
10
20
30
40
50
60
70
80
90
100
Any TEAE[b,c]
Any Related TEAE[c]
Neutropenia[d]
Thrombocytopenia[d]
Anemia[d]
Fatigue
Cytokine Release Syndrome
Nausea
Diarrhea
Constipation
Decreased Appetite
Headache
Dizziness
Hypotension

FIG. 24

FIG. 25


% of Incidence
100
80
60
40
20
0
CRS
NT
CRS or NT
CRS or NT
CRS
NT
1
4
8
15
21
29
Study Day
CRS 91 82 71 60 60 59
NT 91 90 87 77 74 72
CRS or NT 91 82 71 60 57 56



CD4+ Frequency, %
100
75
50
25
0
Post-Leukapheresis
Post-Purification
Mid-Process
Drug Composition
CD8+ Frequency, %
100
75
50
25
0
Post-Leukapheresis
Post-Purification
Mid-Process
Drug Composition

FIG. 26




FIG. 27A

FIG. 27B



Active Caspase 3–negative %
CAR+ T cells
100
75
50
25
0
CD4+
CD8+
Low
Formulation Vol
Low
Formulation Vol

FIG. 27C



CD3+CAR+
200
150
100
50
0
DL1
DL2
CD3+ CAR+ T cell dose in composition,
x 10^6 cells

FIG. 28A



CD4+CAR+
CD8+CAR+
CD4+CAR+ TNF-α+
CD8+CAR+ TNF-α+
CD4+CAR+ CCR7+
CD8+CAR+ CCR7+
DL1
DL2
0
50
100
150
200
CAR+ T cell dose in composition, x 10^6 cells

FIG. 28B




Grade 1
Grade 2
Grade 3
Grade 4
Grade 5
Patients, %
0
10
20
30
40
50
60
70
80
90
100
Any TEAE[b,c]
Any Related TEAE[c]
Neutropenia[d]
Lymphopenia[d]
Thrombocytopenia[d]
Anemia[d]
Fatigue
Cytokine Release Syndrome
Decreased Appetite
Nausea
Cough
Hypotension
Constipation
Diarrhea
Dizziness
Headache
Hypomagnesemia
Leukopenia
Vomiting

FIG. 29

FIG. 30


Population
ORR (95% CI)
n
CORE patient population[a]
46.6 (34.8-58.6)
73
Double/triple hit
62.5 (35.4-84.8)
16
Double expressor
44.4 (13.7-78.8)
9
Never in CR
47.2 (30.4-64.5)
36
Chemosensitive
50 (29.1-70.9)
24
Chemorefractory
44.9 (30.7-59.8)
49
Relapse < 12 m from ASCT
53.3 (26.6-78.7)
15
SD/PD to last chemo
41.2 (24.6-59.3)
34
IPI 3-5
26.9 (11.6-47.8)
26
IPI 0-2
56.8 (41-71.7)
44
0
10
20
30
40
50
60
70
80
90
100
Month 6 ORR (95% CI)



FULL
mDOR (95% CI)
CR: NE (9.2 mo-NE)
All: NE (5.0 mo-NE)
PR: 2.1 mo (1.1 mo-3.9 mo)
Probability of Continued Response, %
100
80
60
40
20
0
Time From First Response, months
0 2 5 8 11 17 23
At Risk
CR 56 48 37 21 15 7 1
PR 20 11 2 1 0
All 76 59 39 22 15 7 1

FIG. 31A



CORE
mDOR (95% CI)
CR: NE (10.2 mo-NE)
All: NE (5.0 mo-NE)
PR: 2.1 mo (1.0 mo-5.0 mo)
Probability of Continued Response, %
100
80
60
40
20
0
Time From First Response, months
0
2
5
8
11
17
23
At Risk
CR 43 37 30 18 12 6 0
PR 15 10 1 1 0
All 58 47 31 19 12 6 0

FIG. 31B



FULL
mOS (95% CI); 12 mo OS (95% CI)
CR: NE (NE-NE); 87% (73%-94%)
All: NE (10.4 mo-NE); 59% (47%-68%)
PR: 10.3 mo (6.8-12.7 mo); 31% (9%-57%)
Nonresponders: 3.6 mo (1.5-6.2 mo); 11% (2%-28%)
Survival, %
100
80
60
40
20
0
0 3 6 9 12 18 24
Overall Survival, months
At Risk
All 102 86 68 48 28 11 0
CR 56 54 47 37 23 10 0
PR 20 19 15 9 3 0
Non-responder 26 13 6 2 2 1 0

FIG. 31C



CORE
mOS (95% CI); 12 mo OS (95% CI)
CR: NE (NE-NE); 89% (72%-96%)
All: NE (10.7 mo-NE); 63% (49%-74%)
PR: 10.3 mo (6.8 mo-NE); 33% (9%-60%)
Nonresponders: 4.5 mo (0.8-6.2 mo); 11% (1%-38%)
Survival, %
100
80
60
40
20
0
Overall Survival, months
0 3 6 9 12 18 24
At Risk
All 73 64 50 37 22 8 0
CR 43 41 35 28 18 8 0
PR 15 14 12 8 3 0
Non-responder 15 9 3 1 1 0

FIG. 31D

FIG. 32A




FIG. 32B




FIG. 32C





FIG. 32D






FIG. 32E




FIG. 32F

FIG. 33



Mean EQ-5D-5L Index Score
0.85
0.84
0.83
0.82
0.81
0.80
0.79
0.8276
0.8099
0.8351
0.8417
0.8444
Baseline (n=90)
Month 1 (n=76)
Month 2 (n=64)
Month 3 (n=52)
Month 6 (n=23)
Assessment Time Point (following CAR+ T cell administration)

FIG. 34




CAR+ T cell compositions
Better
Worse
Mean (SE) Change From Baseline in EQ-5D-5L
0.10
0.05
0.00
−0.05
−0.10
Study Day
1
29
60
90
180
270
Patients, n:
90
76
64
52
23
10

FIG. 35


EQ-5D-5L Health Status Responder Analysis
Patients (%)
70
60
50
40
30
20
10
0
22.4
48.7
28.9
31.3
51.6
17.2
25
57.7
17.3
30.4
56.5
13
A
B
C
Day 29 (n=76)
Month 2 (n=64)
Month 3 (n=52)
Month 6 (n=23)
Assessment Time Point (following CAR+ T cell administration)
≥0.07 Increase
<0.07 Increase and <0.7 Decrease
≥0.7 Decrease




FIG. 36A




FIG. 36B




FIG. 36C




FIG. 36D



Anxiety/Depression
Patients (%)
80
70
60
50
40
30
20
10
0
54
39
6
1
0
66
26
5
3
0
64
31
3
0
2
64
33
2
2
0
74
17
9
0
0
No problem
Slight problems
Moderate problems
Severe problems
Extreme problems
Baseline (n=90)
Month 1 (n=76)
Month 2 (n=64)
Month 3 (n=52)
Month 6 (n=23)

FIG. 36E

FIG. 37



Mean EQ-VAS Score
85
80
75
70
65
60
70
72
78
78
83
Baseline (n=90)
Month 1 (n=76)
Month 2 (n=64)
Month 3 (n=52)
Month 6 (n=23)
Assessment Time Point (following CAR+ T cell administration)

FIG. 38



CAR+ T cell compositions
Better
Worse
Mean (SE) Change From Baseline in EQ-VAS
20
10
0
-10
-20
1
29
60
90
180
270
Study Day
Patients, n:
90
76
64a
52a
23a
10

FIG. 39



DL1S
DL2S
Median Transgene (Range) Copies/µg
10000
1000
100
10
14,300
15,200
8,650
1,370
1,260
2,260
1,710
880
416
2210
78.2
20.8
13.1
5
5
880
260
Study Day
1 2 4 8 11 15 22 29 60
Patients (n)
DL1 6 6 4 6 5 6 6 6 4
DL2 10 – 9 11 11 10 10 10 7
Median (IQR)
DL1 (n=6)
DL2 (n=9)
C_{max} (copies/µg)
9,790 (2,970, 16,800)
24,400 (17,100, 34,900)
T_{max} (day)
17.5 (11, 25.5)
11 (9, 14)
AUC_{0-28} (day•copies/µg)
73,200 (38,000, 153,000)
201,000 (142,000, 468,000)

FIG. 40




CAR+T cell composition Administration
CRS or NE Onset Date
NE or CRS Onset Date
CRS of NE Resolution Date
NE or CRS Resolution Date
mmddyy
mmddyy
mmddyy
mmddyy
Diagnostics
Monitoring
Prophylactic Measures
Monitoring
Monitoring
Hospital Days
Lymphodepletion
TRAE treatment (ie, tocilizumab, corticosteroids, etc)
CRS and/or NE End

FIG. 41


LOS, days
100
80
60
40
20
0
Facility, Drug, and Diagnostic Costs, $
$300,000
$250,000
$200,000
$150,000
$100,000
$50,000
$0
Facility
Drugs
Diagnostics
Median LOS
$13,743
$16,434
$177
$24,945
$79,223
$20,832
$45,384
$31,018
$92,231
$263,743
Grade 1 (n=13)
Grade 2 (n=8)
Grade 1 (n=1)
Grade 2 (n=3)
Grade 3 (n=2)
CRS & NE(s) Grade ≤2 (n=2)
CRS & NE(s) Grade ≥3 (n=4)
CRS & NE(s) Grade ≤2 (n=4)
CRS & NE(s) Grade ≥3 (n=6)
CRS & NE(s) Grade ≥3 (n=1)
CRS Only
NE(s) Only
Nonconcurrent
Concurrent



Higher in CR at 3M
(n=16, 360 genes)
Higher in PD at 3M
(n=29, 380 genes)
Log2 fold-change >.6, <-.6
FDR <= 10%
-log10 FDR
Log2 fold-change
5
4
3
2
1
0
3
2
1
0
-1
-2
-3

FIG. 42




FIG. 43



FL
DLBCL
-Log10(AdjustedPValue)
Estimate
20
15
10
5
0
5
4
3
2
1
0
-1
-2
-3
-4
-5

FIG. 44

FIG. 45A




FIG. 45B




FIG. 46A




FIG. 46B





FIG. 47


R/R Large B-cell lymphomas
RCTs (n=9)
Non-randomized trials (n=29)
Observational studies (n=40)
≥3rd Line of treatment
Salvage therapies
RCTs (n=4)
Non-randomized trials (n=4)
Observational studies (n=4)
CAR T therapies
RCTs (n=0)
Non-randomized trials (n=3)
Observational studies (n=0)
De novo DLBCL (n=2)
Transformed DLBCL (n=2)
PMBCL (n=1)
FL3B (n=1)
SCNSL (n=0)
Mixed population (n=15)b
≥2nd Line of treatment
Transplant-eligible
RCTs (n=3)
Non-randomized trials (n=5)
Observational studies (n=29)
Transplant-ineligible
RCTs (n=4)
Non-randomized trials (n=9)
Observational studies (n=3)
Mixed transplant population
RCTs (n=3)
Non-randomized trials (n=11)
Observational studies (n=16)
De novo DLBCL (n=4)
Transformed DLBCL (n=5)
PMBCL (n=2)
FL3B (n=2)
SCNSL (n=3)
Mixed population (n=60)b



Leukapheresed
N = 342
Reasons for not receiving CAR+ T cells
• Death, n = 33
• Other, n = 9
• Disease-related complications, n = 6
• Product could not be manufactured, n = 2
Received LDC and CAR+ T cells
N = 292
Received nonconforming product,[a] n = 24
Received liso-cel
N = 268
DL1
• LBCL treated set, n = 45
• LBCL efficacy set, n = 40
DL1D
• LBCL treated set, n = 6
• LBCL efficacy set, n = 6
DL2
• LBCL treated set, n = 176
• LBCL efficacy set, n = 168
DL3
• LBCL treated set, n = 41
• LBCL efficacy set, n = 41
LBCL treated set[b]
N = 268
LBCL efficacy set
N = 255
Reasons for exclusions
• No PET-positive disease per IRC assessment before liso-cel administration, n = 4
• No PET scan after bridging therapy and prior to liso-cel administration, n = 6
• Other, n = 3

FIG. 48

FIG. 49A




+ Censored
CR
TOTAL
Median (95% CI) Duration of Response
All patients: 13.3 (8.2–NR) months
Patients with CR: NR (13.3–NR) months
Probability of Continued Response (%)
100
80
60
40
20
0
CR 135 98 81 56 28 26 15 14 1 1 0
Total 186 102 83 58 30 28 15 14 1 1 0
0 3 6 9 12 15 18 21 24 27 30
Duration of Response (Months)
CR
Total

FIG. 49B


+ Censored
CR
TOTAL
Median (95% CI) Progression-free Survival
All patients: 6.8 (3.3–11.8) months
Patients with CR: NR (14.1–NR) months
6-Month (95% CI) Progression-free Survival
All patients: 50.6% (43.8-57.1)
Patients with CR: 75.1 (66.6-81.7)
12-Month (95% CI) Progression-free Survival
All patients: 42.1% (34.9-49.1)
Patients with CR: 62.1 (52.1-70.5)
Probability of Progression-free Survival (%)
100
80
60
40
20
0
CR
Total
135 95 57 26 15 1 0
255 100 59 28 15 1 0
0 5 10 15 20 25 30
Progression-free Survival (Months)
CR
Total



+ Censored
CR
TOTAL
Median (95% CI) Overall Survival
All patients: 19.9 (10.9–NR) months
Patients with CR: NR (NR–NR) months
6-Month (95% CI) Overall Survival
All patients: 74.4% (68.4-79.4)
Patients with CR: 93.8 (88.0-96.8)
12-Month (95% CI) Overall Survival
All patients: 55.4% (49.4-61.9)
Patients with CR: 84.5 (76.4-90.0)
Probability of Overall Survival (%)
100
80
60
40
20
0
CR
Total
135 120 82 47 28 5 1
255 185 98 52 29 5 1
0 5 10 15 20 25 30
Overall Survival (Months)
CR
Total

FIG. 49C

FIG. 50A



Subgroup
Evaluable patients, n
Patients with response, n
ORR (95% CI)
Overall 285 190 73 (67, 78)
PAS 133 99 74 (66, 82)
DLI 40 27 68 (51, 81)
DL2 108 77 74 (65, 81)
DL3 41 32 79 (67, 88)
≥65 years 107 83 77 (69, 85)
<65 years 148 103 70 (62, 77)
Male 160 120 75 (67, 81)
Female 99 70 70 (59, 79)
DLBCL NOS 131 89 68 (59, 76)
HGBCL 33 25 76 (59, 89)
tFL 57 48 84 (72, 93)
Transformed iNHL 18 11 61 (36, 83)
PMBCL 14 11 79 (49, 95)
Bridging therapy, yes 163 101 62 (54, 70)
Bridging therapy, no 106 89 84 (75, 90)
SPD* ≥50 cm² 69 43 62 (50, 74)
SPD* <50 cm² 177 135 77 (70, 83)
CRP* ≥20 mg/L 145 94 65 (56, 73)
CRP* <20 mg/L 109 101 93 (86, 97)
Comorbidities,* yes 80 44 55 (44, 66)
Comorbidities,* no 185 142 77 (70, 83)
Chemotherapy sensitive 85 69 81 (71, 89)
Chemotherapy refractory 110 70 64 (54, 73)
HSCT Yes 87 68 78 (68, 86)
HSCT No 168 118 70 (63, 77)
Outpatients 25 20 80 (59, 93)
0 10 20 30 40 50 60 70 80 90 100
Objective Response Rate (95% CI)

FIG. 50B




Subgroup
Evaluable patients, n
Patients with CR, n
CR rate (95% CI)
Overall 235 135 58 (47, 68)
PAS 133 72 54 (45, 63)
DL1 40 24 60 (43, 75)
DL2 106 55 52 (44, 60)
DL3 41 26 63 (46, 78)
≥65 years 107 65 61 (51, 70)
<65 years 148 70 47 (39, 56)
Male 169 88 53 (45, 61)
Female 66 46 62 (49, 73)
DLBCL NOS 131 63 48 (39, 57)
HGBCL 33 20 61 (42, 77)
tFL 57 36 63 (49, 76)
Transformed iNHL 18 7 39 (17, 64)
PMBCL 14 7 50 (23, 77)
Bridging therapy, yes 130 67 52 (43, 60)
Bridging therapy, no 105 68 65 (55, 74)
SPD[a] ≥50 cm² 69 23 33 (22, 46)
SPD[a] <50 cm² 177 107 61 (53, 68)
CRP[b] ≥20 mg/L 146 65 45 (36, 53)
CRP[b] <20 mg/L 109 67 62 (52, 71)
Comorbidities,[c] yes 40 31 78 (62, 89)
Comorbidities,[c] no 195 104 53 (46, 61)
Chemotherapy sensitive 95 46 48 (38, 57)
Chemotherapy refractory 170 89 52 (45, 60)
HSCT Yes 87 55 63 (52, 73)
HSCT No 188 80 43 (35, 50)
Outpatients 29 14 48 (30, 67)
0 10 20 30 40 50 60 70 80 90 100
Complete Response Rate (95% CI)

FIG. 51A


Censored
PMBCL
tFL
HGL
DLBCL, NOS
tiNHL
Probability of continued response, (%)
100
80
60
40
20
0
HGL 25 15 13 10 6 6 5 4 0
tFL 48 32 27 19 11 10 4 4 0
PMBCL 11 7 5 2 0
tiNHL 11 5 4 1 1 1 0 1
DLBCL, NOS 89 42 33 25 11 10 3 5 1
0 3 6 9 12 15 18 21 24 27 30
Duration of Response (Months)
NHL Subtype HGL tFL PMBCL tiNHL DLBCL, NOS



Censored
PMBCL
tFL
HGL
DLBCL, NOS
tiNHL
Progression-free Probability
100
80
60
40
20
0
HGL 33 20 13 12 7 6 5 4 2 0
tFL 57 39 30 21 14 10 6 4 4 0
PMBCL 14 7 7 4 1 0
tiNHL 18 7 4 2 1 1 0
DLBCL, NOS 131 54 36 30 18 10 7 5 3 1 0
0 3 6 9 12 15 18 21 24 27 30
Progression-free Survival (Months)
NHL Subtype
HGL
tFL
PMBCL
tiNHL
DLBCL, NOS

FIG. 51B




Censored
No
Yes
Probability of continued response, (%)
100
80
60
40
20
0
No 85 50 44 29 14 12 7 7 1 1 0
Yes 101 52 39 29 16 16 8 7 0 0 0
0 3 6 9 12 15 18 21 24 27 30
Duration of Response (Months)
Anticancer Treatment No Yes

FIG. 51C

FIG. 51D


+ Censored
Logrank p=0.4190
Chemosensitive
Chemorefractory
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
5
10
15
20
25
30
Analysis Value
Prior Chemoresponse Status
Chemorefractory
Chemosensitive
Chemorefractory 120 61 36 19 11 1 0
Chemosensitive 66 33 19 9 3 0




Censored
< 50 cm2
>= 50 cm2
Probability of continued response, (%)
100
80
60
40
20
0
Duration of Response (Months)
0
3
6
9
12
15
18
21
24
27
30
< 50 cm^2 136 80 64 44 24 22 14 13 1 1 0
>= 50 cm^2 43 18 16 12 4 4 1 1 1 0 0
Pre-LDC SPD Status
< 50 cm^2
>= 50 cm^2

FIG. 51E

FIG. 51F


+ Censored
Logrank p=0.2534
< 65 years
>=65 years
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
5
10
15
20
25
30
Analysis Value
Age Group
< 65 years
>= 65 years
< 65 years 103 61 35 10 10 1 0
>= 65 years 83 49 20 0 4 0



+ Censored
Logrank p=0.0361
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
5
10
15
20
25
30
Analysis Value
1
2
Pre-LDC CrCL < 60 mL/min or Screening LVEF < 50% vs. Others
1: CrCL < 60 mL/min or LVEF >=40 to < 60%
2: CrCL >= 60 mL/min and LVEF >=50%
1 44 19 10 4 1 0
2 142 76 45 24 13 1 0

FIG. 51G

FIG. 52A




FIG. 52B




FIG. 53A





FIG. 53B






FIG. 54A

FIG. 54B




FIG. 54C
Fatigue

FIG. 54D
Pain

FIG. 55A




FIG. 55B




FIG. 56



SUBJECTS
1
2
3
4
5
6
7
8
9
10
11
13
PD
PD
PD
Days
1
30
60
90
120
150
180
210
240
270
Response: CR PR PD
Monitoring: Inpatient Outpatient

FIG. 57
TREATMENT FOR CRS AND NE




FIG. 58



Median follow-up (95% CI), 12 (11.2-16.7) months
Censored
CR
Median (95% CI: NR (NR, NR) months
Total
Median (95% CI: NR (8.5, NR) months
Median (95% CI: 1.9 (1.1, 2.1) months
PR
Probability of continued response, (%)
100
80
60
40
20
0
CR 136 106 91 79 48 43 25 23 1 1 0
PR 50 4 2 2 2 2 0 0 0 0 0
Total 186 110 93 81 60 45 26 23 1 1 0
0 3 6 9 12 15 18 21 24 27 30
Duration of Response (Months)
Response Group CR PR Total

FIG. 59



Subgroup
Evaluable Patients, n
ORR Rate (95% CI)
CR Rate (95% CI)
Overall 256 73 (67, 78) 53 (47, 59)
Age
≥65 years 108 76 (67, 84) 60 (50, 70)
<65 years 148 70 (62, 78) 48 (40, 56)
Subtype
DLBCL NOS 131 68 (59, 76) 49 (40, 58)
tFL 57 84 (72, 93) 63 (49, 76)
Transformed iNHL 57 61 (36, 83) 39 (17, 64)
PMBCL 18 78 (48, 95) 50 (23, 77)
HGBCL 33 76 (58, 77) 61 (42, 77)
Bridging therapy
Yes 150 67 (59, 75) 45 (37, 54)
No 106 80 (71, 87) 64 (54, 73)
High disease burden*
Yes 99 63 (52, 72) 36 (27, 47)
No 149 80 (72, 85) 64 (55, 72)
HSCT
Yes 87 78 (68, 86) 63 (52, 73)
No 168 70 (63, 77) 48 (40, 56)
Secondary CNS lymphoma
Yes 6 50 (12, 88) 50 (12, 88)
No 250 73 (67, 79) 53 (47, 60)
0 10 20 30 40 50 60 70 80 90 100
ORR Rate (95% CI)
0 10 20 30 40 50 60 70 80 90 100
CR Rate (95% CI)

FIG. 60



Response Group CR PR Non-responder Total
Censored
Median follow-up (95% CI): 12.3 (12.0, 17.5)
Median (95% CI: NR (NR, NR) months CR
Median (95% CI: 6.8 (3.3, 14.1) months Total
Median (95% CI: 2.8 (2.1, 3.0) months PR
Non-responder
Progression-free Probability, (%)
100
80
60
40
20
0
Progression-free Survival, (Months)
0 3 6 9 12 15 18 21 24 27 30
CR 138 116 93 85 63 45 31 23 14 1 0
PR 50 14 2 2 2 2 2 0
Non-responder 70 3 0
Total 258 133 100 87 65 47 33 23 14 1 0

FIG. 61




Response Group CR PR Non-responder Total
Censored
Median (95% CI): NR (NR, NR) CR
Median (95% CI): 21.1 (13.3, NR) Total
Median (95% CI): 9.0 (6.0, 10.4) PR
Median (95% CI): 6.1 (2.9, 6.5) Non-responder
Probability of Overall Survival (%)
100
80
60
40
20
0
Overall Survival (Months)
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45
CR 136 135 128 113 94 68 48 36 26 16 13 8 5 1 0
PR 50 45 33 20 8 3 3 0
Non-responder 70 41 27 14 7 3 1 1 1 1 1 1 1 0
Total 258 221 188 147 109 74 52 37 27 17 14 9 6 1 0

FIG. 62


NHL Subtype HGL tFL PMBCL tiNHL DLBCL, NOS
Censored
Median (95% CI): 12.1 (1.8, 12.1) PMBCL
Median (95% CI): NR (11.8, NR) tFL
Median (95% CI): 5.0 (2.8, NR) HGL
Median (95% CI): 2.9 (1.3, NR) tiNHL
Median (95% CI): 3.0 (2.8, 6.3) DLBCL, NOS
Progression-free Probability
100
80
60
40
20
0
0 3 6 9 12 15 18 21 24 27 30
Progression-free Survival (Months)
HGL 33 20 13 13 10 9 6 4 2 0
tFL 57 41 34 27 17 15 12 9 7 0
PMBCL 14 7 7 7 5 0
tiNHL 18 7 5 3 3 1 1 1 1 0
DLBCL, NOS 131 56 40 36 29 21 13 8 4 1 0




CAR+ T cells by qPCR and flow vs. CD19+ B cells
CD19+ B-cell
CD3+ truncated receptor+
Transgene
Transgene, Copies/mL (IQR)
CAR-CD3 or CD19+ B cells, Cells/mL (IQR)
Transgene
CD3+ truncated receptor+
CD19+ B cell
Study Day
1
4
8
11
15
22
29
60
90
180
270
365

FIG. 63

FIG. 64


CAR+ T cells (CD3+, CD8+ and CD4+) by flow
CD3+ truncated receptor+
CD4+ truncated receptor+
CD8+ truncated receptor+
CD3+ truncated receptor+
CD8+ truncated receptor+
CD4+ truncated receptor+
CD3+/CD4+/CD8+ EGFRt+ or CD19+ B-cell (cells/µL)
Study Day
1
4
8
11
15
22
29
60
90
180
270
365